Combining Weight-Loss Surgery With GLP-1 Medicine for Obesity
Tests weight-loss surgery with a GLP-1 medicine in adults living with obesity.
Plain-language title generated from the registry record
Registry title: Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
Key facts
- Where
- Baotou, Beijing, Datong, Jinan, Kunming, Xingtai, and Zhengzhou, ChinaSee the 7 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 70 years old?
Source: NCT07732738, who can take part
Where in China
- The Second Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and TechnologyBaotou, ChinaTaking people
- China-Japan Friendship HospitalBeijing, ChinaTaking people
- Sinopharm Tongmei General HospitalDatong, ChinaTaking people
- The Second Hospital, Cheeloo College of Medicine, Shandong UniversityJinan, ChinaTaking people
- The First People Hospital Of Yunnan ProvinceKunming, ChinaTaking people
- Xingtai Ninth HospitalXingtai, ChinaTaking people
- Zhengzhou Central HospitaZhengzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China-Japan Friendship Hospital
- Trial code
- NCT07732738
- Record updated
- 29 July 2026
- Original description
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits.Read full original descriptionShow less
The Efficacy and Safety of Bariatric Surgery Combined With GLP-1 Receptor Agonists for Patients With Obesity: A Prospective, Multicenter Cohort Study
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits.
Given the lack of multi-regional validation in China's diverse population, this multicenter study aims to confirm the real-world effectiveness and generalizability of bariatric surgery plus GLP-1RA across distinct regional cohorts.
Inclusion: Primary metabolic surgery candidates: Patients undergoing initial laparoscopic sleeve gastrectomy (LSG); obesity:BMI ≥27.5 kg/m²; Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria; Age range: 16-70 years (inclusive); Informed consent: Willing participation with documented consent.
Exclusion: Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively; Prior bariatric surgery: History of any metabolic/bariatric surgical procedure; Non-indicated candidates: Patients not meeting standard bariatric surgery indications; Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak); Significant comorbidities:; Advanced hepatic/renal dysfunction (Child-Pugh C or eGFR <30 mL/min/1.73m²) Active malignancy (except non-melanoma skin cancers) Autoimmune disorders requiring immunosuppression Uncontrolled psychiatric conditions (e.g., active psychosis, severe depression).